Symlin Complete Response Follows "Emerging Consensus" On Hypoglycemia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amylin expects its hypoglycemia re-analysis to mitigate FDA’s concerns about its pending antidiabetic Symlin, the company says.